BRAIN AG expands patent protection for Aurase^(R) enzyme for the treatment of chronic wounds

• Patent protection in 20 countries of the most important entry markets
• Possible fields of application address, among others, the growing markets for the treatment of chronic wounds
• BRAIN engaged in discussions regarding different partnership options in the BioIndustrial business segment

Zwingenberg, March 21, 2017: B.R.A.I.N. Biotechnology Research and Information Network AG ("BRAIN AG"; ISIN DE0005203947 / WKN 520394) has obtained far-reaching patent protection for a newly developed enzyme with the product name Aurase^(R). For a total of 20 countries in Europe, Asia, North America, Oceania and Africa, this laid the foundation for the later marketing of applications based on Aurase^(R) in the fields of skin and scar treatment as well as the strongly growing market for the care of chronic wounds. The development of Aurase^(R) is part of the portfolio of BRAIN's BioIndustrial business segment. Currently, BRAIN is evaluating concrete application possibilities for Aurase^(R) and is engaged in discussions with industrial partners regarding different marketing strategies.

Aurase^(R) offers the possibility to improve the efficient and conservative treatment of chronic wounds in hospitals and surgeries as well as in home-based health care. Substantial tests have shown that Aurase^(R) is efficient and well-tolerated. In the meantime, development activities in BRAIN's laboratories are well advanced and they are targeted at achieving a clearly enhanced production method for Aurase^(R).

"With Aurase^(R) we are further expanding our BioIndustrial business segment, which is dedicated to the development and marketing of our products and product components via own sales channels or in cooperation with partner companies," according to Dr Jürgen Eck, CEO of BRAIN AG. "The comprehensive protection of our inventions by patent law here is an important prerequisite."

There is an increasing number of patients with chronic wounds in Germany, Europe and other regions of the world. Experts believe that the current number is about three to four million people in Germany, who suffer from it, with an increasing tendency. Mostly elderly people are affected. Therefore the demographic change has an impact on the number of diseases. Another factor are diet-related diseases such as excess weight, diabetes or malnutrition.

The annual sales volume of the markets potentially addressed by BRAIN for wound treatment is estimated by experts to reach more than EUR 100 million in Europe alone. BRAIN intends to participate with Aurase^(R)-based products in this.

A more detailed version of this press release can be found at https://www.brain-biotech.de/en/press.
 

About BRAIN

BRAIN is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. Today, BRAIN's business model is based on two pillars -"BioScience" and "BioIndustrial". The first pillar, "BioScience", comprises its - frequently exclusive -collaboration business with industrial partners. The second pillar "BioIndustrial" comprises the development and commercialisation of BRAIN's own products and active product components. Further information is available at www.brain-biotech.de/en.
 

Contact:

B.R.A.I.N
Biotechnology Research And Information Network AG
Dr. Martin Langer
Executive Vice President
Corporate Development
Darmstädter Str. 34-36
64673 Zwingenberg, Germany

Tel.: +49-6251-9331-16
Fax: +49-6251-9331-11
E-Mail: ir@brain-biotech.de
www.brain-biotech.de

Disclaimer

This press release contains forward- looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.